Randomized Double-blind, Placebo-controlled, Multicenter Clinical Study of Nimotuzumab Combined With Trifluridine/Tipiracil in Third-line and Beyond for the Treatment of Metastatic Colorectal Cancer

This is a randomized, double-blind, placebo-controlled, multicenter study. The main purpose of the study is to evaluate the clinical efficacy and safety of nimotuzumab combined with trifluridine/tipiracil in third-line and beyond for the treatment of metastatic colorectal cancer (mCRC). This study planned to be divided into two parts: Part A and Part B. Part A (safety run-in) with a 3 + 3 study design, which primary endpoint is safety; Part B (main study) with a prospective, randomized, double-blind, placebo-controlled design, which primary endpoint is overall survival (OS).

开始日期2024-04-01

申办/合作机构

百泰生物药业有限公司

NCT06333821 / Not yet recruiting临床3期

A Multicentre, Prospective, Randomized, Double-blind, Placebo-controlled Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Locally Advanced Cervical Squamous Cell Carcinoma

The purpose of this study is to evaluate the efficacy and safety of nimotuzumab plus concurrent chemoradiotherapy sequential maintenance therapy versus placebo combined with concurrent chemoradiotherapy in patients with locally advanced cervical squamous cell carcinoma.
The primary hypotheses are that nimotuzumab plus concurrent chemoradiotherapy sequential maintenance therapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free survival.

开始日期2024-04-01

申办/合作机构

百泰生物药业有限公司

NCT06259721 / Recruiting临床2期IIT

Efficacy and Safety of Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma: A Single-arm, Open-label, Multi-center Phase II Clinical Trial

The purpose of this study is to explore the efficacy and safety of a combination regimen of Anti-PD1 monoclonal antibody, nimotuzumab, and capecitabin in treating recurrent or metastatic nasopharyngeal carcinoma patients who have failed first-line platinum-based chemotherapy.

开始日期2024-02-10

申办/合作机构

江西省肿瘤医院

100 项与尼妥珠单抗相关的临床结果

登录后查看更多信息

100 项与尼妥珠单抗相关的转化医学

登录后查看更多信息

100 项与尼妥珠单抗相关的专利（医药）

登录后查看更多信息

386

项与尼妥珠单抗相关的文献（医药）

2023-12-01·The Kaohsiung Journal of Medical Sciences

miR‐199a/214 cluster enhances prostate cancer sensitiveness to nimotuzumab via targeting TBL1XR1

Article

作者: Lu, Qiang ; Duan, Yi-Xing ; Wang, Yong ; Guo, Xi ; Hu, Sheng ; Zhou, Qiang

Abstract:

Prostate cancer (PCa) is a significant health concern affecting men worldwide. Previous studies have shown that nimotuzumab, a drug targeting the epidermal growth factor receptor (EGFR), can effectively inhibit cancer progression. Here, we aimed to explore the role of miR‐199a/214 cluster in mediating the inhibitory effect of nimotuzumab on the development of PCa. In this study, we conducted an MTT assay to assess cell proliferation and utilized flow cytometry to evaluate cell apoptosis and cell cycle arrest. To investigate the molecular mechanisms underlying the effects of nimotuzumab on prostate cancer development, we focused on the miR‐199a‐5p and miR‐214‐3p miRNA clusters. The TargetScan Human database was used to predict the binding sites between miR‐199a‐5p or miR‐214‐3p and the 3'‐UTR of the transducin (β)‐like 1 X‐linked receptor 1 (TBL1XR1) mRNA. To confirm the direct interaction and binding between miR‐199a‐5p or miR‐214‐3p and the 3'‐UTR of TBL1XR1 mRNA, we performed luciferase reporter assays. Our findings demonstrated that nimotuzumab exerted a significant dosage‐dependent suppression of PCa cell proliferation and facilitated PCa cell apoptosis and cell cycle arrest. Concurrently, nimotuzumab obviously impeded the activity of Wnt/β‐catenin and EGFR signaling pathways in PCa cells. We also observed downregulation of miR‐199a‐5p and miR‐214‐3p in PCa cells. Overexpression of miR‐199a/214 cluster inhibited PCa cell viability and enhanced cell apoptosis. Furthermore, we found that miR‐199a/214 cluster augmented the inhibitory effect of nimotuzumab on PCa cell proliferation and promoted its ability to induce apoptosis and cell cycle arrest. This effect was reversed upon TBL1XR1 overexpression, indicating that TBL1XR1 is involved in the regulatory pathway of miR‐199a/214 and nimotuzumab in PCa cells. We further revealed that TBL1XR1 was overexpressed in PCa and was identified as a downstream target of the miR‐199a/214 cluster. In nimotuzumab‐treated PCa cells, the overexpression of miR‐199a/214 markedly inhibited Wnt/β‐catenin and EGFR signaling, and this effect was also rescued by TBL1XR1 overexpression. In summary, our data indicated that miR‐199a/214 cluster play a crucial role in enhancing the inhibitory effect of nimotuzumab on PCa development by downregulating TBL1XR1 and modulating Wnt/β‐catenin and EGFR signaling pathways. These findings offer a novel therapeutic approach for the treatment of prostate cancer.

2023-11-23·British Journal of Cancer

Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial

Article

作者: Shi, Anhui ; Ma, Hu ; Zhu, Xiaodong ; Han, Chun ; Wang, Jun ; Zheng, Anping ; Wu, Xiaoyuan ; Wang, Xiaohong ; Fan, Ruitai ; Zhu, Jun ; Huerxidan, Niyazi ; Yu, Jinming ; Meng, Xue ; Yan, Senxiang ; Qu, Zhongyu ; Ye, Ming ; Li, Guang ; Sun, Xindong ; Wang, Buhai ; Dai, Chunhua

BACKGROUND:

This prospectively randomised, double-blinded, placebo-controlled, multicenter Phase 3 clinical trial was conducted to assess the efficacy and safety profile of nimotuzumab (nimo) plus concurrent chemo-radiotherapy (CCRT) in patients with unresectable locally advanced ESCC.

METHODS:

Patients were randomly assigned (1:1) to receive CCRT plus nimotuzumab or placebo. The primary endpoint was overall survival (OS). In addition, interim analysis for short-term response rate was pre-defined.

RESULTS:

A total of 201 patients were randomised into two groups. Eighty patients in the nimo group and eighty-two in the placebo group were evaluable. Three to six months after treatment, 26 (32.5%) patients achieved complete response (CR) in the nimo group, and 10 (12.2%) in the placebo group (P = 0.002). The ORR of the nimo group was significantly higher than the placebo group (93.8% vs. 72.0%, P < 0.001). The two groups' grade 3-5 adverse drug reactions were 11.1% vs. 10.9% (P > 0.05).

CONCLUSIONS:

Nimotuzumab, in combination with chemo-radiotherapy, increased the CRR and ORR with a good safety profile. The OS is needed to be followed and finally analysed.

CLINICAL TRIAL REGISTRATION:

NCT02409186.

2023-11-20·Journal of Clinical Oncology

Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer

Article

作者: Bai, Yuxian ; Fu, Deliang ; Xu, Ruihua ; Zhang, Hongmei ; Shen, Lin ; Zhang, Jun ; Bai, Xianhong ; Wang, Qiong ; Hao, Chunyi ; Pan, Hongming ; Zhong, Haijun ; Cheng, Ying ; Chen, Donghui ; Yang, Jianwei ; Qin, Baoli ; Chen, Zhendong ; Wang, Zishu ; Qin, Shukui ; Li, Jin ; Yang, Lin ; Xu, Jianming ; Liu, Tianshu ; Chen, Jia ; Yuan, Ying ; Zheng, Qingshan

K-Ras pancreatic cancers benefit overall survival in phase 3 NOTABLE study.

项与尼妥珠单抗相关的新闻（医药）

2024-04-25

·BiG生物创新社

ASCO 2024丨这些中国临床专家，将分享最新重磅研究

2024年美国临床肿瘤学会(ASCO)年会将于5月31日到6月4日在芝加哥举办，是世界上规模最大、学术水平最高、最具权威性的临床肿瘤学会议，会议汇集了全球肿瘤学医生和专业人士、患者倡导者、工业界代表和主要媒体，共同探讨当前国际最前沿的研究发现和临床试验成果。ASCO成立于1964年,是世界上最大、最具影响力的肿瘤专业学术组织,致力于癌症的预防、治疗及改善对患者的护理。ASCO在全球150多个国家和地区拥有超过45,000名成员。4月24日晚，ASCO官网公布了本次大会的研究标题，几十余名中国专家将在世界舞台上展示其研究成果，报告涵盖了多个瘤种的最新治疗策略和技术，展示了中国在全球癌症研究中的重要地位和贡献。世易编辑团队精心整理了中国专家们的研究报告，供您参考。全体大会报告Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study. Abstract: LBA4 · Suresh S. Ramalingam教授，美国埃默里大学Winship癌症研究所· 陆舜教授，上海交通大学附属胸科医院口头报告Lung Cancer—Non-Small Cell MetastaticSacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study. Abstract: 8502 · 方文峰教授，中山大学肿瘤防治中心 Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial. Abstract: 8508 · 张力教授，中山大学肿瘤防治中心 Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Adjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected EGFR-mutated stage II–IIIA non-small-cell lung cancer (ICTAN, GASTO1002): A randomized phase 3 trial. Abstract: 8004 ·王思愚教授，中山大学肿瘤防治中心 A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091). Abstract: 8008 · 刘慧教授，中山大学肿瘤防治中心 Taiwan national lung cancer early detection program for heavy smokers and non-smokers with family history of lung cancer. Abstract: 8009 · Pan-Chyr Yang, MD, PhD，台湾大学医学院 Gastrointestinal Cancer—Colorectal and Anal Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study. Abstract: 3505 · 徐瑞华教授，中山大学肿瘤防治中心 Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Abstract: 6505 · 王迎教授，中国医学科学院血液病医院 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia CLAMP: A phase II prospective study of camrelizumab combined with pegaspargase, etoposide, and high-dose methotrexate in patients with natural killer (NK)/T-cell lymphoma. Abstract: 7002 · 刘涛教授，华中科技大学同济医学院附属协和医院 Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study. Abstract: LBA7003 · 赵维莅教授，上海交通大学医学院附属瑞金医院 Hematologic Malignancies—Plasma Cell DyscrasiaPhase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ). Abstract: 7500 ·Thierry Facon, MD，University of Lille, CHU Lille·刘卓刚教授，中国医科大学附属盛京医院Central Nervous System Tumors Efficacy and safety of the vebreltinib in patients with previously treated, secondary glioblastoma/IDH mutant glioblastoma with PTPRZ1-METFUsion GENe (FUGEN): A randomised, multicentre, open-label, phase II/III trial. Abstract: 2003 · Zhaoshi Bao, MD, PhD，首都医科大学附属北京天坛医院 High-dose almonertinib in treatment-naïve EGFR-mutated NSCLC with CNS metastases: Efficacy and biomarker analysis. Abstract: 2007 · 范云教授，浙江省肿瘤医院 SarcomaUpdated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma. Abstract: 11502 · 邱海波教授，中山大学肿瘤防治中心 Sintilimab, doxorubicin and ifosfamide (AI) as first-line treatment in patients with advanced undifferentiated pleomorphic sarcoma (UPS), synovial sarcoma (SS), myxoid liposarcoma (MLPS) and de-differentiated liposarcoma (DDLPS): A single-arm phase 2 trial. Abstract: 11505 · 罗志国教授，复旦大学附属肿瘤医院 ARTEMIS-002: Phase 2 study of HS-20093 in patients with relapsed or refractory osteosarcoma. Abstract: 11507 · 谢璐教授，北京大学人民医院 Head and Neck Cancer Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial. Abstract: LBA6000 · 刘需教授，中山大学肿瘤防治中心 Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial. Abstract: 6001 · 陈秋燕教授，中山大学肿瘤防治中心 Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A phase III, prospective, randomised-controlled, multicenter clinical trial. Abstract: 6002 · 康敏教授，广西医科大学第一附属医院 Developmental Therapeutics—ImmunotherapyClaudin18.2-targeted chimeric antigen receptor T cell-therapy for patients with gastrointestinal cancers: Final results of CT041-CG4006 phase 1 trial. Abstract: 2501 · 齐长松教授，北京大学肿瘤医院 A potential best-in-class BCMA-CD19 bispecific CART with advanced safety by self-inhibiting IFNG signaling during CRS. Abstract: 2502 · Lei Xue Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies. Abstract: 2504 · Chang Liu, MD，北京大学肿瘤医院Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors.Abstract: 3002· Wungki Park, MD, MS，美国纪念斯隆凯瑟琳癌症中心· 张剑教授，复旦大学附属肿瘤医院Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors. Abstract: 3008 · 赵军教授，北京大学肿瘤医院快速口头摘要报告 Lung Cancer—Non-Small Cell Metastatic A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study. Abstract: 8513 · James Chih-Hsin Yang 教授，台大肿瘤中心 Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study. Abstract: 8520 · 李玮教授，同济大学附属上海市肺科医院 Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer. Abstract: 8014 · 陈大卫教授，山东省肿瘤医院 Breast Cancer—Metastatic ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC). Abstract: 1020 · 胡夕春教授，复旦大学附属肿瘤医院 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Efficacy and safety of cadonilimab in combination with pulocimab and paclitaxel as second-line therapy in patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer who failed immunochemotherapy: A multicenter, double-blind, randomized trial. Abstract: 4012 · 张小田教授，北京大学肿瘤医院 Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC). Abstract: 4019 · 章琦教授，浙江大学医学院附属第一医院肝胆胰外科 Gastrointestinal Cancer—Colorectal and Anal Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors (TNTCRT): A multicenter, randomized, open-label, phase 3 trial. Abstract: LBA3511 · Xin Wang, MD，四川大学华西医院 Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion. Abstract: 3514 · Hangyu Zhang，浙江大学医学院第一附属医院 Three-year disease-free survival after transanal vs. laparoscopic total mesorectal excision for rectal cancer (TaLaR): A randomized clinical trial. Abstract: 3516 · 康亮教授，中山大学附属第六医院 Genitourinary Cancer—Kidney and Bladder Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: A single-arm, open-label, phase 2 trial. Abstract: 4511 · Zhigong Wei，四川大学华西医院 Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Latest results of a phase 2 study of IMM01 combined with azacitidine (AZA) as the first-line treatment in adults with higher risk myelodysplastic syndromes (MDS). Abstract: 6510 · Wei Yang，中国医科大学附属盛京医院 Safety and efficacy of CD7-CAR-T cell in patients with relapsed/refractory T-lymphoblastic leukemia/lymphoma: Phase I dose-escalation/dose-expansion study. Abstract: 6515 · Lijuan Hu, MD, 北京大学人民医院 Hematologic Malignancies—Plasma Cell Dyscrasia OriCAR-017, a novel GPRC5D-targeting CAR-T, in patients with relapsed/refractory multiple myeloma: Long term follow-up results of phase 1 study (POLARIS). Abstract: 7511 · Shan Fu，浙江大学医学院附属第一医院 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Timdarpacept (IMM01) in combination with tislelizumab in prior anti-PD-1 failed classical Hodgkin lymphoma: An open label, multicenter, phase II study (IMM01-04) evaluating safety as well as preliminary anti-tumor activity. Abstract: 7017 · Zhenjiu Wang, MD Gynecologic Cancer Efficacy and safety of sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer: A phase II trial. Abstract: 5512 ·刘继红教授，中山大学肿瘤防治中心 Nimotuzumab plus concurrent chemoradiotherapy for locally advanced cervical squamous cell carcinoma: The randomized, phase 3 CC3 study. Abstract: 5514 ·王俊杰教授，北京大学第三人民医院 A phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer (SCORES). Abstract: LBA5516 · 袁光文教授，中国医学科学院肿瘤医院 Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A final overall survival analysis of a multicenter, open-label, randomized, phase 3 trial. Abstract: 5520 · 臧荣余教授，复旦大学附属中山医院 Head and Neck Cancer Preliminary results of phase I/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors. Abstract: 6013 · 阮丹云教授，中山大学肿瘤防治中心 Covalent FAPI PET enables accurate management of medullary thyroid carcinoma: a prospective single-arm comparative clinical trial. Abstract: LBA6018 · Ziren Kong, MD, 中国医学科学院北京协和医学院 Sarcoma A phase II study of anlotinib and an anti-PDL1 antibody in patients with alveolar soft part sarcoma: Results of expansion cohorts. Abstract: 11515 · 刘佳勇教授，北京大学肿瘤医院 Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST). Abstract: 11518 · 李健教授，北京大学肿瘤医院 Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors. Abstract: 3012 · 沈琳教授，北京大学肿瘤医院 9MW2821, a nectin-4 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1/2a study. Abstract: 3013 · 张剑教授，复旦大学附属肿瘤医院 Developmental Therapeutics—Immunotherapy Phase I study of GUCY2C CAR-T therapy IM96 in patients with metastatic colorectal cancer. Abstract: 2518 · 齐长松教授，北京大学肿瘤医院 Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: A phase 1 dose escalation and expansion study. Abstract: 2519 · 郑莉教授，四川大学华西医院 Symptom Science and Palliative Care Effect of nurse-led multi-disciplinary treatment on patients with head and neck tumors: A randomized controlled trial. Abstract: 12013 · Jingjing Wang, MD，四川大学华西医院肿瘤中心临床科学研讨会A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort. Abstract: 5509 · Hui Xie，德琪医药有限公司临床研发部 KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. Abstract: LBA8509 · Tony S. K. Mok 教授，香港大学 Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study. Abstract: 104 · 樊英教授，中国医学科学院肿瘤医院 Efficacy of disitamab vedotin (RC48) plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junction adenocarcinoma: A multicenter, single-arm, phase II trial (RCTS). Abstract: 4009 · 刘联教授，山东大学齐鲁医院 A novel and uniquely designed bispecific antibody (LBL-024) against PD-L1 and 4-1BB in patients with advanced malignant tumors and neuroendocrine carcinoma: A report of safety and robust efficacy of LBL-024 monotherapy in phase I/II, first-in-human, open-label, multicenter, dose escalation/expansion study. Abstract: 4010 · 张盼盼医生，北京大学肿瘤医院 Safety and efficacy of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with advanced pancreatic ductal adenocarcinoma: Preliminary results from a phase 1 study. Abstract: 4011 · 郝继辉教授，天津医科大学肿瘤医院 Neoadjuvant sintilimab and platinum-doublet chemotherapy followed by transoral robotic surgery for HPV-associated resectable oropharyngeal cancer: Single-arm, phase II trial. Abstract: 6011 · 宋明教授，中山大学肿瘤防治中心 BiG 十周年预告本次BiG十周年庆典，将首次分为国内和国际篇章，以原创科学和临床需求为出发点，讨论创新技术平台和创新疗法（PROTACT/分子胶、双抗/ADC、siRNA/ASO、CGT、AI制药）的重大进展和发展前景，十年一药曙光现，大浪淘沙始见金！▼报名参会会议门票：审核制(免费)；含主论坛+分论坛，不含餐；优先biotech/Pharma、临床、院校科学家共建Biomedical创新生态圈！如何加入BiG会员？

ASCO会议临床结果

2024-04-01

·医药观澜

2024年第一季度，NMPA批准超30款新药/新适应症（附PDF下载）

▎药明康德内容团队报道根据中国国家药监局（NMPA）官网批件信息统计：2024年第一季度共有17款新药*在中国首次获批上市，其中包括了6款1类新药，来自科济药业、科州制药、恒瑞医药、四环医药、罗氏（Roche）、卫材（Eisai）/渤健（Biogen）；同时也有18款新药在中国实现了新适应症或新剂型获批上市。在我们统计的超30个新药/新适应症的获批信息中，抗肿瘤适应症占比最多，其次是罕见病适应症；同时，阿尔茨海默病、偏头痛等神经系统疾病也迎来多款新疗法。本文就让我们来一起看看第一季度获批的新药有哪些亮点。（*新药统计范围包括化学药品1类和5.1类、治疗用生物制品1类和3.1类，未统计疫苗类产品）扫描下方二维码，可获取《2024年第一季度中国获批上市新药》完整数据PDF文件。亮点一、10多款抗肿瘤新药获批，单抗药物占55%从适应症来看，第一季度获批新药中，抗肿瘤新药占比最多，共有10多款新药获批用于治疗不同类型的肿瘤，包括肝细胞癌、胃癌、非小细胞肺癌、乳腺癌、胰腺癌、头颈部肿瘤、胆道癌、NTRK融合儿童实体瘤、多发性骨髓瘤、黑色素瘤等。这些新药的分子类型包括单抗、小分子药物和CAR-T细胞疗法。其中，有4款抗PD-1/L1单抗产品获批新适应症。包括：百济神州的替雷利珠单抗在中国获批第12项适应症，单药用于肝细胞癌患者的一线治疗；君实生物的特瑞普利单抗在中国获批第7项适应症，用于可切除非小细胞肺癌围手术期治疗；默沙东（MSD）的帕博利珠单抗在中国获批第13个适应症，用于局部晚期或转移性胆道癌患者的一线治疗；基石药业的舒格利单抗在中国获批第5项适应症，用于胃及胃食管结合部腺癌的一线治疗。PD-1/L1抑制剂之外，还有一些其它抗体药物获批肿瘤适应症。例如，罗氏的抗HER2单抗复方制剂帕妥珠曲妥珠单抗注射液（皮下注射），获批用于治疗成人HER2阳性早期和转移性乳腺癌患者。与标准静脉给药的数小时相比，这款皮下注射的复方制剂可以实现5~8分钟完成治疗，为乳腺癌患者带来更为便捷的治疗选择。此外，百泰生物的抗EGFR单抗尼妥珠单抗在中国获批头颈部鳞癌新适应症，该药此前已经在中国获批治疗鼻咽癌、胰腺癌。同时，第一季度还有4款小分子新药收获了肿瘤适应症。其中，科州制药的MEK抑制剂妥拉美替尼为首次获批，用于含PD-1/PD-L1治疗失败的NRAS突变的晚期黑色素瘤患者。此外，还有3款小分子新药获批新适应症，分别为：百时美施贵宝公司的注射用紫杉醇（白蛋白结合型），获批用于转移性胰腺癌的一线治疗；齐鲁制药的ALK/ROS1抑制剂伊鲁阿克，获批一线治疗ALK阳性非小细胞肺癌，将适应症拓展至覆盖全部ALK阳性局部晚期或转移性非小细胞肺癌者人群；罗氏的TRK/ROS1酪氨酸激酶抑制剂恩曲替尼胶囊，获批治疗1月龄以上NTRK融合儿童实体瘤患者，该产品具有中枢神经系统（CNS）活性，在针对颅外实体瘤或原发性CNS肿瘤儿童患者时表现出快速和持久的缓解。在细胞与基因疗法领域，科济药业靶向BCMA的自体CAR-T细胞疗法泽沃基奥仑赛注射液在中国获批上市，用于治疗经过至少3线治疗后进展的复发或难治性多发性骨髓瘤成人患者。公开资料显示，这也是中国获批上市的第5款CAR-T细胞疗法，以及第二款靶向BCMA的CAR-T细胞治疗药物。亮点二、优先审评助力，多款罕见病新药获批在今年第一季度获批的新药中，有7款为罕见病新药，其中有5款罕见病新药是通过优先审评程序获批。罗氏的新型抗C5循环单克隆抗体可伐利单抗在中国获批用于未接受过补体抑制剂治疗的阵发性睡眠性血红蛋白尿症（PNH）成人和青少年患者，患者可进行每四周一次皮下注射。PNH是一种罕见且危及生命的血液疾病。值得一提的是，本次获批是可伐利单抗在全球所有国家中的首次获批，同时这也是罗氏第一次在中国实现一款创新药的全球首发。另一款在中国实现全球首发的新药是勃林格殷格翰（Boehringer Ingelheim）的罕见皮肤病创新药佩索利单抗（皮下注射制剂），获批用于减少12岁及以上青少年和成人的泛发性脓疱型银屑病（GPP）发作。GPP是一种罕见的、复发性或持续发作的严重皮肤疾病。佩索利单抗是一款皮下注射的抗IL-36R单抗，其在临床研究中能显著降低GPP发作风险84%长达48周。武田（Takeda）有两款罕见病新药在中国获批上市。其一是注射用替度格鲁肽获批治疗短肠综合征（SBS）成人和1岁及以上儿童患者。根据武田新闻稿，这也是中国首个治疗短肠综合征的人胰高血糖素样肽2（GLP-2）类似物，它可以帮助患者提高剩余肠管的吸收功能，帮助降低甚至摆脱对肠外营养支持的依赖。其二是重组猪FⅧ（rpFⅧ）药物注射用舒索凝血素α，在中国获批用于获得性血友病A成人患者按需治疗和出血事件的控制。图片来源：123RF其它获批的罕见病新药还包括：Orphalan公司的铜离子络合剂四盐酸曲恩汀薄膜衣片，获批治疗成人、青少年和≥5岁儿童的威尔逊病（又称肝豆状核变性）。威尔逊病是一种罕见的慢性遗传病，因肝脏铜转运受损而可能威胁生命。诺贝仁制药（Nobelpharma）的铜吸收抑制剂醋酸锌片也在中国获批治疗威尔逊病。作为一种锌制剂，该药能阻止铜在肠道的吸收，并清除沉积于组织中的铜，可作为威尔逊病的治疗方式之一。苏庇医药（Sobi）的IL-1受体拮抗剂阿那白滞素注射液则在中国获批两项新适应症，分别用于治疗斯蒂尔病（Still’s disease）和冷吡啉相关周期性综合征（CAPS）。值得一提的是，这两种罕见病均已经在中国被纳入《第二批罕见病目录》。亮点三：阿尔茨海默病、偏头痛等疾病迎来新疗法除了抗肿瘤和罕见病新药，第一季度在中国获批上市的新药还包括了至少4款精神/神经系统新药，适应症涵盖多动症、偏头痛、阿尔茨海默病等。其中，有两款CGRP受体拮抗剂在中国获批上市，分别为：礼来（Eli Lilly and Company）公司的加卡奈珠单抗注射液，获批用于成人偏头痛的预防性治疗；辉瑞公司（Pfizer）的瑞美吉泮口崩片，获批用于成年人有或无先兆偏头痛的急性治疗。偏头痛是一种失能性神经疾病，被世界卫生组织（WHO）列为10种致残性“最强”的内科疾病之一。CGRP信号通路已经成为治疗偏头痛的热门靶点。本次这两款新药相继在中国获批，无疑为中国的偏头痛患者带来福音。阿尔茨海默病领域也迎来好消息。卫材/渤健的仑卡奈单抗注射液在中国获批治疗早期阿尔茨海默病（AD）。仑卡奈单抗是一款抗可溶性β淀粉样蛋白（Aβ）单克隆抗体，也是近年来靶向β淀粉样蛋白的第二款创新阿尔茨海默病疗法。这是一类“疾病修饰治疗”方法，其核心在于其对阿尔茨海默病的疾病发病机制进行干预，靶向清除患者大脑中过多的Aβ原纤维和Aβ斑块，从“源头”解决问题，而不仅仅是缓解症状或对症状进行管理。图片来源：123RF另外，祐儿医药的盐酸哌甲酯缓释干混悬剂获批用于治疗6岁及6岁以上注意缺陷多动障碍（ADHD，俗称多动症）。这是一款长效液体剂型，口服后45分钟起效、作用时间持续长达12小时，且口服溶液对于不愿意吞咽的儿童接受度更高。这是祐儿医药的盐酸哌甲酯获批的第二个剂型，该产品的缓释咀嚼片已于去年12月在中国获批上市。除了上述提到的新药，2024年第一季度还有一些其它新药、2类改良型新药/复方制剂、疫苗、生物类似药等在中国获批，限于篇幅，本文不再一一介绍。祝贺这些药物在中国获批上市，它们的到来将使更多患者拥有新的治疗选择。扫描下方二维码，可获取《2024年第一季度中国获批上市新药》完整数据PDF文件。（PDF文件包含新药、2类改良型新药/复方制剂、疫苗、生物类似药等）参考资料：[1]中国国家药监局（NMPA）官网. From https://www.nmpa.gov.cn/zwfw/zwfwpjfbzs/index.html[2]各公司官方新闻稿本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医药观澜」微信公众号留言联系我们。其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

上市批准细胞疗法免疫疗法核酸药物疫苗

2024-03-27

·米内网

22个西药品牌厉害了！“神药”暴涨134%，石药、百济神州上榜，国产1类新药亮眼

精彩内容北上广是国内医药大市，米内网数据显示，2023年重点城市公立医院终端化学药（含生物药，下同）销售额超1800亿元，广州蝉联榜首、北京位列第二、上海回归第三。北上广三城第一畅销品类仍是抗肿瘤和免疫调节剂，随着集采、国谈持续推进，品牌TOP10不断洗牌，石药、齐鲁、复宏汉霖上榜，国产单抗类药物表现亮眼。2023年北上广公立医院终端化学药城市格局（单位：亿元）来源：米内网重点城市公立医院化学药终端竞争格局北京：降糖“神药”暴涨134%，石药一枝独秀米内网数据显示，2023年北京市公立医院终端化学药销售额超过210亿元，同比增长7.03%，创历史新高。从治疗领域上看，抗肿瘤和免疫调节剂为第一畅销品类，市场份额超过26%；其次为全身用抗感染药物、消化系统及代谢药、血液和造血系统药物，市场份额皆超过12%。北京市公立医院终端化学药年度销售趋势（单位：亿元）来源：米内网重点城市公立医院化学药终端竞争格局品牌TOP10销售额均超过1亿元，领军品牌“大换血”，默沙东的帕博利珠单抗注射液首次跻身榜首，销售额超过2亿元；赛诺菲的度普利尤单抗注射液首次位列第二、诺和诺德的司美格鲁肽注射液强势闯进前三。进口品牌霸屏，石药百克的聚乙二醇化重组人粒细胞刺激因子注射液是唯一上榜的国产品牌。2023年北京市公立医院终端化学药品牌TOP10来源：米内网重点城市公立医院化学药终端竞争格局从销售额增速上看，诺和诺德的司美格鲁肽注射液暴涨133.98%，石药百克的聚乙二醇化重组人粒细胞刺激因子注射液、百特的人血白蛋白、赛诺菲的度普利尤单抗注射液涨幅皆超过30%。诺和诺德的司美格鲁肽是一款GLP-1受体激动剂，全球已获批上市的适应症有2型糖尿病、减重。据诺和诺德财报，2023年司美格鲁肽全球销售额1458.11亿丹麦克朗（212亿美元），其中司美格鲁肽注射液Ozempic（2型糖尿病）收入957.18亿丹麦克朗（139亿美元），同比增长60%。在国内，司美格鲁肽于2021年获批用于治疗2型糖尿病，同年12月进入国家医保目录，市场进入快速放量阶段，后续减肥适应症获批将进一步带动销售。10个品牌中，阿托伐他汀钙片为第一批集采品种、注射用美罗培南为第七批集采品种，近年来市场持续承压。2023年立普妥（阿托伐他汀钙片）排名进一步跌至第五，销售额下滑5.32%。注射用美罗培南集采结果于2022年11月落地执行，石药欧意供应北京地区，2023年原研厂家日本住友销售额下滑18.88%，石药欧意销售额上涨43.37%。上海：9大品牌涨逾15%！复宏汉霖亮了米内网数据显示，2023年上海市公立医院终端化学药销售额接近180亿元，同比增长20.10%，但未超过疫情前水平。从治疗领域上看，抗肿瘤和免疫调节剂以超过26.72%的市场份额领跑；消化系统及代谢药、血液和造血系统药物分别位列第二、第三，市场份额皆超过13%。上海市公立医院终端化学药年度销售趋势（单位：亿元）来源：米内网重点城市公立医院化学药终端竞争格局品牌TOP10中，抗肿瘤和免疫调节剂有6个、血液和造血系统药物有3个、全身用抗感染药物有1个。盖立复的人血白蛋白蝉联榜首，西南药业的注射用头孢唑肟钠首次跃居第二，三生制药的重组人血小板生成素注射液蝉联第三。2023年上海市公立医院终端化学药品牌TOP10来源：米内网重点城市公立医院化学药终端竞争格局除了罗氏的注射用曲妥珠单抗销售额下滑1.13%，其余9个品牌销售额皆涨逾15%。其中，复宏汉霖的利妥昔单抗注射液暴涨98.88%，西南药业的注射用头孢唑肟钠大涨44.22%，齐鲁制药的贝伐珠单抗注射液大涨36.86%。对比北上广三城的公立医院终端化学药品牌TOP10，上海有5个国产品牌上榜，超过北京（1个）、广州（4个）。随着罗氏的贝伐珠单抗、利妥昔单抗先后跌出品牌TOP10榜单，复宏汉霖的利妥昔单抗、齐鲁制药的贝伐珠单抗于2023年成功替代原研药，取得一席之地。复宏汉霖的利妥昔单抗注射液最早于2019年获批上市，为国内首款生物类似药。米内网数据显示，2023年重点城市公立医院终端利妥昔单抗销售额超过13亿元，复宏汉霖占据42.88%市场份额，首次超越罗氏。此前国内已有复宏汉霖、信达生物、正大天晴的利妥昔单抗生物类似药获批上市，近日国药集团的利妥昔单抗注射液获批上市，成为国产第4家。广州：8款抗肿瘤药霸屏！石药、齐鲁、百济神州上榜米内网数据显示，2023年广州市公立医院终端化学药销售额超过220亿元，连续三年创历史新高，再次在北上广当中领跑。从治疗领域上看，抗肿瘤和免疫调节剂为第一畅销品类，市场份额高达35.87%；血液和造血系统药物位列第二，市场份额超过12%；全身用抗感染药物位列第三，占比11%。广州市公立医院终端化学药年度销售趋势（单位：亿元）来源：米内网重点城市公立医院化学药终端竞争格局品牌TOP10中，5个产品销售额超过2亿元。抗肿瘤药上榜产品多达8个，除了奥希替尼、多柔比星，其余抗肿瘤药产品均为单抗类药物。齐鲁制药的贝伐珠单抗注射液首次跻身榜首，阿斯利康的甲磺酸奥希替尼片位列第二，石药欧意的盐酸多柔比星脂质体注射液位列第三。2023年广州市公立医院终端化学药品牌TOP10来源：米内网重点城市公立医院化学药终端竞争格局从销售额变化上看，阿斯利康的甲磺酸奥希替尼片略微下滑0.52%，其在北京市公立医院终端销售额则大跌12.62%。百泰生物的尼妥珠单抗注射液、默沙东的帕博利珠单抗注射液涨幅皆超过50%，齐鲁制药的贝伐珠单抗注射液、百济神州的替雷利珠单抗注射液皆涨逾45%。石药集团在北上广三城的品牌TOP10中均占有一席之地，上榜北京、上海的产品皆是聚乙二醇化重组人粒细胞刺激因子注射液，而在广州上榜的产品是盐酸多柔比星脂质体注射液。盐酸多柔比星脂质体注射液属于纳米高端制剂，目前国内仅有5家企业获批生产，石药集团为该产品首家过评企业。令人欣喜的是，以往上榜的单抗类药物都是进口品牌，近年来随着国内药企创新能力提高，国产生物类似药、国产创新单抗类药物先后在榜单上取得一席之地。此次有2款国产创新单抗类药物首次上榜，具体为百济神州的替雷利珠单抗、百泰生物的尼妥珠单抗注射液。百泰生物的尼妥珠单抗是一款靶向表皮生长因子受体（EGFR）的人源化单克隆抗体，于2008年1月首次在国内获批用于治疗鼻咽癌，成为国内首个治疗恶性肿瘤的单抗类药物，2023年6月再获批联合吉西他滨治疗胰腺癌。该产品已于2017年进入国家医保目录，近年来市场规模不断创新高。数据来源：米内网数据库注：米内网重点城市公立医院化学药终端竞争格局是以北京、上海、广州等20个重点城市样本医院的化学药采购数据为基础，对化学药全品类进行连续监测的样本城市样本医院数据库。上述销售额以产品在终端的平均零售价计算。本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

财报免疫疗法核酸药物带量采购

100 项与尼妥珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	尼妥珠单抗	L01XC	DB06192

研发状态

适应症	最高研发状态	国家/地区	公司
食管癌	批准上市	古巴更多	-
胶质瘤	批准上市	印尼更多	Innogene Kalbiotech Pte Ltd. 更多
头颈部肿瘤	批准上市	古巴更多	Gilead Sciences, Inc. 更多
弥漫内生性脑桥神经胶质瘤	临床2期	中国更多	百泰生物药业有限公司更多
宫颈癌	终止	巴西更多	Eurofarma Laboratórios SA 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02395016 (CTgov)	临床3期	胰腺癌	90	Gemcitabine+Nimotuzumab (Nimotuzumab- Gemcitabine Group)	築製鹹壓壓壓繭簾鑰襯(築顧淵積襯鹽築鹽獵蓋) = 範壓願窪襯憲顧憲築遞夢壓鏇構選觸觸艱鬱夢 (鑰願鑰艱積餘遞艱鬱遞, 齋選鹽積蓋淵築鏇繭壓 ~ 餘願構製糧積築齋鏇範) 更多	-	2024-04-04
				Placebo+Gemcitabine (Placebo-Gemcitabine Group)	築製鹹壓壓壓繭簾鑰襯(築顧淵積襯鹽築鹽獵蓋) = 鏇積製鏇獵鑰簾觸鹹簾夢壓鏇構選觸觸艱鬱夢 (鑰願鑰艱積餘遞艱鬱遞, 積簾醖鹽鹽壓膚願鹽築 ~ 蓋鑰艱積蓋築顧醖醖積) 更多
ESMO_ASIA2023	N/A	晚期鼻咽癌 Epidermal Growth Factor Receptor (EGFR)	-	Nimotuzumab + Chemoradiation	醖糧醖顧鹹顧鑰築觸鹽(艱壓願願構襯餘繭遞鏇): HR = 0.56 (95% CI, 0.32 ~ 0.96), P-Value = 0.0328 更多	积极	2023-12-02
				Nimotuzumab
ESMO2023	N/A	胰腺癌一线	282	Routine chemotherapy	簾齋蓋衊鹹願網遞餘觸(齋築淵鑰齋簾醖鏇積範) = 窪願構獵衊選觸顧顧淵遞鹹衊膚選齋壓顧鹽齋 (鑰襯襯廠夢獵窪築鏇淵 )	积极	2023-10-23
				Nimotuzumab combined with routine chemotherapy	簾齋蓋衊鹹願網遞餘觸(齋築淵鑰齋簾醖鏇積範) = 襯夢夢簾選繭鬱遞積繭遞鹹衊膚選齋壓顧鹽齋 (鑰襯襯廠夢獵窪築鏇淵 )
APACT study (ESMO2023)	N/A	胰腺癌辅助	795	Adjuvant chemotherapy with nimotuzumab	憲獵膚壓構壓簾鏇窪鹽(膚鏇壓鹽鑰築壓襯簾築) = 夢淵壓醖衊衊膚鏇構願餘製觸艱鑰鏇艱簾構淵 (繭窪製顧鹹憲鹹積襯糧 ) 更多	积极	2023-10-23
				Adjuvant chemotherapy without nimotuzumab	憲獵膚壓構壓簾鏇窪鹽(膚鏇壓鹽鑰築壓襯簾築) = 淵獵顧鹹醖願糧膚蓋夢餘製觸艱鑰鏇艱簾構淵 (繭窪製顧鹹憲鹹積襯糧 ) 更多
NCT04976478 (ESMO2023) 人工标引	N/A	宫颈鳞状细胞癌	122	Nimotuzumab + radiotherapy	鑰鑰衊獵膚鏇餘鏇廠鹽(鏇膚糧餘壓憲憲繭淵蓋) = 蓋鏇獵網膚願糧製醖構鑰繭艱鑰願淵網鏇簾襯 (顧襯鑰觸鹹網窪築繭顧 ) 更多	积极	2023-10-22
NCT04678791 (ESMO2023) 人工标引	N/A	宫颈鳞状细胞癌	291	Nimotuzumab +CCRT	淵獵衊鏇觸製餘膚繭繭(艱廠網壓醖膚夢淵製襯) = 觸觸窪鑰餘選夢鑰鏇糧鑰觸製鏇憲顧範遞鑰鬱 (鬱窪蓋觸顧鏇蓋網製蓋 ) 更多	积极	2023-10-22
				CCRT	淵獵衊鏇觸製餘膚繭繭(艱廠網壓醖膚夢淵製襯) = 觸齋鹹糧膚鏇鑰夢鏇選鑰觸製鏇憲顧範遞鑰鬱 (鬱窪蓋觸顧鏇蓋網製蓋 ) 更多
NCT04949503 (ASCO2023) 人工标引	N/A	局部晚期头颈部鳞状细胞癌	612	Control group (no nimotuzumab)ment	製獵觸壓齋鑰鹹膚遞憲(鬱鬱選鏇積壓築範鹹遞) = 餘襯構鏇窪積範蓋壓積鏇獵艱廠膚鏇醖壓廠簾 (願鹹簾廠艱製糧觸鑰築 ) 更多	积极	2023-05-31
				Control group (no nimotuzumab)	製獵觸壓齋鑰鹹膚遞憲(鬱鬱選鏇積壓築範鹹遞) = 獵顧艱憲鏇壓蓋願醖膚鏇獵艱廠膚鏇醖壓廠簾 (願鹹簾廠艱製糧觸鑰築 ) 更多
ASCO2023	N/A	胰腺癌	104	Nimotuzumab + Gemcitabine plus nab-paclitaxelGemcitabine plus nab-paclitaxel	餘鹽遞積願製蓋壓憲獵(鹽餘鬱餘襯齋網齋觸淵) = 鏇鹹選鑰鬱繭選膚願繭夢齋夢鏇範顧糧鹽淵網 (壓願繭構憲壓鑰鹹築窪 ) 更多	积极	2023-05-31
CSCO2022	N/A	转移性头颈部鳞状细胞癌 \| 复发性头颈部鳞状细胞癌	30	尼妥珠单抗	築窪鏇醖壓願衊夢網淵(憲衊鹹夢顧艱糧襯糧構) = 餘憲夢製簾壓醖獵蓋願壓範構願範簾艱構齋蓋 (獵製壓鑰醖憲壓衊艱淵 )	积极	2022-09-21
NCT02395016 (ASCO2022) 人工标引	临床3期	胰腺癌 KRAS Wild-type	92	gemcitabine 1000 mg/m2+Nimotuzumab 400 mg	膚夢夢襯鏇衊願範遞鹹(繭窪鬱觸範壓蓋鑰鏇願) = 築鹹網糧艱遞蓋廠淵願鹹衊鹹夢衊淵襯窪鬱夢 (簾顧構衊襯獵壓顧積繭 ) 更多	积极	2022-06-08
				gemcitabine 1000 mg/m2+placebo	膚夢夢襯鏇衊願範遞鹹(繭窪鬱觸範壓蓋鑰鏇願) = 範簾淵憲願膚糧製膚選鹹衊鹹夢衊淵襯窪鬱夢 (簾顧構衊襯獵壓顧積繭 ) 更多